Mabwell (Shanghai) Bioscience Balance Sheet Health
Financial Health criteria checks 4/6
Mabwell (Shanghai) Bioscience has a total shareholder equity of CN¥1.9B and total debt of CN¥2.0B, which brings its debt-to-equity ratio to 106.8%. Its total assets and total liabilities are CN¥4.5B and CN¥2.6B respectively.
Key information
106.8%
Debt to equity ratio
CN¥2.03b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥1.59b |
| Equity | CN¥1.90b |
| Total liabilities | CN¥2.59b |
| Total assets | CN¥4.50b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 688062's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 688062's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 688062's net debt to equity ratio (23.6%) is considered satisfactory.
Reducing Debt: 688062's debt to equity ratio has increased from 0% to 106.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688062 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688062 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.